Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

Freiburg, May 7th, 2025

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid (NCA) in primary sclerosing cholangitis (PSC).

NUC-5 (NCT03872921) is a double-blind, placebo-controlled trial enrolling 301 patients with PSC, who receive either 1,500 mg NCA or placebo for a total of 192 weeks. At the primary data analysis after 96 weeks of treatment, the primary endpoint of combined partial normalization of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no worsening of disease stage on histology was achieved by a statistically significantly greater proportion of patients receiving NCA than placebo. Significant superiority of NCA was also observed in multiple secondary endpoints. The safety results revealed similar rates of study patients with adverse events and serious adverse events between the NCA and placebo groups.

The topline results from NUC-5 will be presented during the Late Breaker session on Saturday, May 10, 2025 at the EASL Congress in Amsterdam.

PSC is a rare, progressive disease in which the immune system attacks the bile ducts in the liver, which leads to fibrosis, or the formation of scar tissue. A considerable proportion of patients develop bile duct, liver, or colorectal cancer, while many others eventually progress to cirrhosis of the liver. No approved pharmaceutical treatment is currently available, and the most effective treatment option is liver transplantation.

“Finding a medicine that effectively treats PSC has been a challenge in the field of hepatology for decades” said Prof. Michael Trauner, Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria and principal investigator of the trial. “After so many disappointments in this space, the first positive results from a phase 3 study on PSC is a watershed moment for people with PSC, their families, physicians and the entire PSC community. The results of this study will not only advance patient care but will also give researchers new insights into the disease itself”.

“We are very excited about the positive results of the NUC-5 trial, which was the largest clinical trial on PSC to date which compared biopsies from patients before and after treatment” said Dr. Kai Pinkernell, Managing Director Science and Innovation for Dr. Falk Pharma. “A trial of this duration and involvement is a major undertaking, and we thank all of the participating patients, investigators, and trial staff for their dedication to this trial”.

About norucholic acid

Norucholic acid is an engineered bile acid derivative. Unlike endogenous bile acids, it undergoes no meaningful amidation with glycine or taurine, allowing NCA to be absorbed from bile by cholangiocytes and subsequently re-secreted into bile by hepatocytes in a process called cholehepatic shunting. This together with putative direct anti-inflammatory and anti-fibrotic mechanisms are thought to confer protective effects in PSC. In a previous phase 2 trial, 12 weeks of treatment with NCA was shown to significantly reduce levels of alkaline phosphatase (ALP).

About NUC-5

NUC-5 is a randomized, double-blind, placebo-controlled trial enrolling 301 patients with biopsy-confirmed PSC and levels of ALP at least 1.5-fold greater than the upper limit of normal (ULN). The combined primary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (Ludwig classification). The key secondary endpoint was partial normalization of ALP to <1.5-fold ULN and no worsening of disease stage by histology (modified Nakanuma staging).

At week 96, 15.1% of patients receiving NCA achieved the primary endpoint compared to 4.2% of placebo patients (p = 0.0048). Similarly, 15.1% of NCA patients versus 5.1% of placebo patients achieved the key secondary endpoint (p = 0.0086). NCA treatment led to improvement by at least 1 Ludwig stage for 25.2% of NCA patients compared to 10.5% of placebo patients (p = 0.0217). Furthermore, worsening by at least one Ludwig stage was observed in 40.4% of placebo patients compared to 20.3% of NCA patients (p = 0.0069). Blood levels of multiple liver enzymes improved under NCA but not placebo. NCA was well tolerated, with similar rates of serious adverse events between the two arms.

NUC-5 is still ongoing, with patients receiving continuous double-blind treatment with either NCA or placebo for an additional 96 weeks. Additional results will be reported after the conclusion of all 192 weeks of double-blind treatment. Patients completing all 192 weeks of double-blind treatment will have the option of receiving open-label treatment with NCA for up to 72 weeks.

Read the abstract here (LBO-001)

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1400 individuals globally and 340 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com


Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis


THỦ THUẬT HAY

Hướng dẫn cách đặt vé máy bay Vietnam Airlines trực tuyến

Vietnam Airlines là hãng hàng không lớn nhất Việt Nam hiện nay và là hãng hàng không 4 sao duy nhất ở Việt Nam đáp ứng đầy đủ các điều kiện của tiêu chuẩn hàng không thế giới. Chính vì vậy giá vé của Vietnam Airlines

Microsoft phát hành bản cập nhật tích lũy 14393.1613 cho người dùng Windows 10 Anniversary

Vào ngày hôm qua, Microsoft đã phát hành bản cập nhật tích lũy build 14393.1613 cho người dùng Windows 10 Anniversary. Bản cập nhật này không bao gồm bất kì tính năng nào mới, nhưng nó chứa nhiều bản sửa lỗi hữu ích.

6 lời khuyên giúp dữ liệu an toàn khi ra đường

Trong cuộc sống ngày nay, điện thoại thông minh và máy tính bảng đang trở thành 'vật bất ly thân', bởi vì chúng mang lại cho người dùng nhiều lợi ích và chứa đựng nhiều thông tin cá nhân quan trọng. Nếu thường xuyên

Cách làm sao để màn hình Laptop luôn sáng

Đối với những người thường xuyên làm việc trước màn hình máy tính thì việc màn hình thường xuyên tắt gây ra sự khó chịu tột cùng, để khắc phục điều ngày họ thường cài đặt thời gian chờ từ 20 đến 30 phút.

Làm trong suốt mọi thứ trên Windows một cách hiệu quả với Glass2k

Phần mềm Glass2k đã có từ rất lâu, trong bài viết này mình sẽ hướng dẫn các bạn cách sử dụng. Qua đó khiến giao diện Windows 10 trở nên bóng bẩy hơn.

ĐÁNH GIÁ NHANH

Cùng xem cuộc so găng giữa Canon 77D và Nikon D7500

77D – sản phẩm có số serie rất đặc biệt của Canon đang được đưa lên bàn cân để so sánh với chiếc máy mới ra mắt của Nikon là D7500. Xét về phân khúc thì cả hai đều thuộc dòng semi-pro trong khi thời gian ra mắt cũng

iPhone 13 và iPhone 13 mini ra mắt: Nâng cấp mạnh tay nhưng giá chỉ từ 15.9 triệu đồng

Ra mắt cách đây không lâu nhưng iPhone 13 và iPhone 13 mini đã để lại ấn tượng cho người dùng với nhiều nâng cấp mạnh mẽ và mức giá khởi điểm chỉ 15.9 ...

Đánh giá Acer Asprise F5 - 573 - 39Q0 Thiết kế sang trọng, thời lượng pin cao

Acer Aspire F5 là một chiếc laptop hội tụ 3 yếu tố: Thiết kế sang trọng – Hiệu năng ổn định – Giá cả phải chăng. Nó đủ sức gánh vác nhu cầu làm việc văn phòng cũng như giải trí khi căng thẳng. Dù trọng lượng còn lớn...